Short answer
Axogen, Inc. (AXGN) filed an 8-K current report with the SEC on September 10, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). $200.0M cash acquisition of BioCircuit, adding NerveTape and ConformaWrap peripheral-nerve repair products.
Axogen, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $200.0M cash acquisition of BioCircuit, adding NerveTape and ConformaWrap peripheral-nerve repair products
- Funding planned through public offering of 4,910,000 shares at $42.50, with 736,500-share overallotment option
- Gross offering proceeds of approximately $208.7M before expenses, intended to fund the acquisition
- Fourth-quarter 2026 closing depends on IP-license consent, note conversion and electronics-business spin-out
- Integration execution and uncertain commercial benefits create material acquisition risk; no termination fee disclosed
Item 7.01 · Regulation FD Disclosure
- Exhibits 99.1–99.3 furnished under Regulation FD, making accompanying disclosures publicly available
- Materials not deemed filed under Exchange Act Section 18, limiting liability exposure
- Exhibits excluded from automatic incorporation into future SEC filings unless specifically referenced
Item EX-99.1 · Exhibit EX-99.1
- $200M cash acquisition of BioCircuit, subject to customary adjustments and $1.0M post-closing holdback
- NerveTape™ adds the first FDA-approved sutureless peripheral nerve repair device, broadening Axogen’s addressable market
- Funding planned through net proceeds from a public common-stock offering, creating potential shareholder dilution
- Expected fourth-quarter 2026 closing, conditional on customary approvals and BioCircuit electronics-business spin-out
- Management expects 2027 revenue contribution and first-year accretion to gross margin, adjusted EBITDA margin and adjusted EPS
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Axogen, Inc. 8-K filings
Get the next AXGN 8-K as it lands
Follow AXGN for push alerts, or ask the research agent what this filing means.